Venture
Affiliations
Albert Einstein College of Medicine
Technologies
Therapeutic
Indication
Autoimmune & Inflammation
Drug Discovery
Infectious Disease
Bow Therapeutics is developing isolation of human monoclonal antibodies against Chikungunya Virus Glycoprotein using Single B-cell sorting Technology.
Bow Therapeutics Team: